Kwang Dong Pharmaceutical

009290 · KOSPI · South Korea

Public Market Listing

009290KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Kwang Dong Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
bremelanotide(Vyleesi)
Phase 2
MC4RPeptide
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 March 2025Topline resultbremelanotideBMT-801 Phase 2 obesity co-administration study meets primary endpoint
Q1 2025Topline resultbremelanotidePhase 2 of bremelanotide with tirzepatide met its primary endpoint

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.2B$6.4M$98M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.2B$7.4M$79M—report ↗
2023-FY$1.2B$12M$60M—report ↗